Published in Pharma Investments, Ventures and Law Weekly, July 30th, 2006
The purpose of the transaction is to explore Q-MED's technology for the management of osteoarthritis in joints and to explore other orthopedic uses and diseases.
The two companies have entered into a licensing and supply agreement under which Q-MED AB has granted Smith & Nephew Inc. the global exclusive right to market, sell and distribute Durolane and other products intended for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.